---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025172"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2026-05-26T12:30:22+00:00"
generated_at: "2026-05-26T12:35:14.545916+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma announces discovery of pan-viral inhibitors with <50 nM potency against hantavirus

## Summary
- Novel pan-viral inhibitors target L-protein of Andes hantavirus; IC50 <50 nM against hantaan virus in vitro.
- Company expanding platform from CDI-988 (Phase 1b norovirus) to hantavirus, bunyavirus, influenza.
- No approved treatments or vaccines for hantaviruses; Andes strain linked to recent cruise ship outbreak with 3 deaths.
- Plans to evaluate activity against Andes hantavirus replication enzyme and explore partnerships.

## SEC filing metadata
- accession: 0001493152-26-025172
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2026-05-26T12:30:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315226025172/0001493152-26-025172-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315226025172/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025172
- JSON: https://secwatch.observer/filing/0001493152-26-025172.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025172.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.